Literature DB >> 32399461

Aberrant Expression of Peroxisome Proliferator-Activated Receptors in Colorectal Cancer and Their Association with Cancer Progression and Prognosis.

Musa Yaghoubizadeh1, Leila Pishkar2, Gholam Basati3,4.   

Abstract

INTRODUCTION: Peroxisome proliferator-activated receptors (PPARs), PPARα, PPARγ, and PPARδ, are nuclear ligand-activated transcription factors which presumably contribute to a broad range of pathophysiological processes, such as tumorigenesis. Nevertheless, their exact role as tumor suppressors or promoters is not straightforward in colorectal cancer (CRC). Therefore, expression values of these PPARs and their relation with tumor progression and prognosis were examined in CRC patients.
METHODS: In this work, the relative expression values of the PPARs were measured by real-time polymerase chain reaction in 100 CRC tumor tissues paired with adjacent normal tissues. After that, the association between relative expression values of the PPARs in tumor tissues and the cancer progression-related clinicopathological characteristics as well as overall survival of patients were assessed.
RESULTS: While PPARα and PPARδ seemed to be overexpressed, PPARγ was suppressed in CRC tumor tissues compared with paired adjacent normal tissues (p = 0.0001). The relative expressions of PPARα and PPARδ were negatively associated with tumor size, tumor grade, TNM stage, metastasis, lymphatic invasion, and decreased overall survival time (p < 0.05). The same associations, but in reverse direction, were found for PPARγ.
CONCLUSIONS: It was found that PPARα and PPARδ were overexpressed while PPARγ was suppressed in CRC tumor tissues, and these deregulations are associated with cancer progression and poor prognosis.
Copyright © 2020 by S. Karger AG, Basel.

Entities:  

Keywords:  Colorectal cancer; PPARα; PPARγ; PPARδ; Prognosis; Tumor tissue

Year:  2019        PMID: 32399461      PMCID: PMC7206611          DOI: 10.1159/000503995

Source DB:  PubMed          Journal:  Gastrointest Tumors        ISSN: 2296-3774


  38 in total

Review 1.  PPARδ signaling regulates colorectal cancer.

Authors:  Mengli You; Shuping Yuan; Juanjuan Shi; Yongzhong Hou
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

2.  Alteration of gene expression in normal-appearing colon mucosa of APC(min) mice and human cancer patients.

Authors:  Ling-Chun Chen; Chun-Yi Hao; Yanek S Y Chiu; Patrick Wong; Jane S Melnick; Martin Brotman; John Moretto; Fredrick Mendes; Andrew P Smith; James L Bennington; Dan Moore; Nancy M Lee
Journal:  Cancer Res       Date:  2004-05-15       Impact factor: 12.701

3.  Deregulation of tumor angiogenesis and blockade of tumor growth in PPARbeta-deficient mice.

Authors:  Sabine Müller-Brüsselbach; Martin Kömhoff; Markus Rieck; Wolfgang Meissner; Kerstin Kaddatz; Jürgen Adamkiewicz; Boris Keil; Klaus J Klose; Roland Moll; Andrew D Burdick; Jeffrey M Peters; Rolf Müller
Journal:  EMBO J       Date:  2007-07-19       Impact factor: 11.598

4.  A role for peroxisome proliferator-activated receptor gamma in resveratrol-induced colon cancer cell apoptosis.

Authors:  Virginie Aires; Bertrand Brassart; Annie Carlier; Alessandra Scagliarini; Stéphane Mandard; Emeric Limagne; Eric Solary; Laurent Martiny; Michel Tarpin; Dominique Delmas
Journal:  Mol Nutr Food Res       Date:  2014-06-30       Impact factor: 5.914

Review 5.  Establishing the Role of PPARβ/δ in Carcinogenesis.

Authors:  Jeffrey M Peters; Frank J Gonzalez; Rolf Müller
Journal:  Trends Endocrinol Metab       Date:  2015-10-18       Impact factor: 12.015

6.  Primer3--new capabilities and interfaces.

Authors:  Andreas Untergasser; Ioana Cutcutache; Triinu Koressaar; Jian Ye; Brant C Faircloth; Maido Remm; Steven G Rozen
Journal:  Nucleic Acids Res       Date:  2012-06-22       Impact factor: 16.971

7.  HMGCS2 enhances invasion and metastasis via direct interaction with PPARα to activate Src signaling in colorectal cancer and oral cancer.

Authors:  Shih-Wen Chen; Chiang-Ting Chou; Cheng-Chi Chang; Yue-Ju Li; Szu-Ta Chen; I-Ching Lin; Sang-Heng Kok; Shih-Jung Cheng; Jang-Jaer Lee; Tai-Sheng Wu; Min-Liang Kuo; Been-Ren Lin
Journal:  Oncotarget       Date:  2017-04-04

Review 8.  Peroxisome proliferator-activated receptors (PPARs) are potential drug targets for cancer therapy.

Authors:  Qian Gou; Xin Gong; Jianhua Jin; Juanjuan Shi; Yongzhong Hou
Journal:  Oncotarget       Date:  2017-07-27

Review 9.  Tumor Heterogeneity in Primary Colorectal Cancer and Corresponding Metastases. Does the Apple Fall Far From the Tree?

Authors:  Annika Blank; Daniel Edward Roberts; Heather Dawson; Inti Zlobec; Alessandro Lugli
Journal:  Front Med (Lausanne)       Date:  2018-08-31

10.  High-fat diet enhances stemness and tumorigenicity of intestinal progenitors.

Authors:  Semir Beyaz; Miyeko D Mana; Jatin Roper; Dmitriy Kedrin; Assieh Saadatpour; Sue-Jean Hong; Khristian E Bauer-Rowe; Michael E Xifaras; Adam Akkad; Erika Arias; Luca Pinello; Yarden Katz; Shweta Shinagare; Monther Abu-Remaileh; Maria M Mihaylova; Dudley W Lamming; Rizkullah Dogum; Guoji Guo; George W Bell; Martin Selig; G Petur Nielsen; Nitin Gupta; Cristina R Ferrone; Vikram Deshpande; Guo-Cheng Yuan; Stuart H Orkin; David M Sabatini; Ömer H Yilmaz
Journal:  Nature       Date:  2016-03-03       Impact factor: 49.962

View more
  3 in total

1.  The Expression of PPAR Pathway-Related Genes Can Better Predict the Prognosis of Patients with Colon Adenocarcinoma.

Authors:  Xiao-Yu Zhou; Jian-Qi Wang; Jin-Xu Chen; Jing-Song Chen
Journal:  PPAR Res       Date:  2022-04-18       Impact factor: 4.385

Review 2.  PPARs and Tumor Microenvironment: The Emerging Roles of the Metabolic Master Regulators in Tumor Stromal-Epithelial Crosstalk and Carcinogenesis.

Authors:  Hong Sheng Cheng; Yun Sheng Yip; Eldeen Kai Yi Lim; Walter Wahli; Nguan Soon Tan
Journal:  Cancers (Basel)       Date:  2021-04-29       Impact factor: 6.639

Review 3.  Renal Cell Cancer and Obesity.

Authors:  Anna Gluba-Brzózka; Jacek Rysz; Janusz Ławiński; Beata Franczyk
Journal:  Int J Mol Sci       Date:  2022-03-21       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.